Agios and Royalty Pharma Announce $255 Million Purchase Agreement for IDHIFA® Royalty

by NASDAQ Market News June 12, 2020

NASDAQ Market News
Click here to email author

Aptose Presents Early Phase 1a/b CG-806 Clinical Findings at the 25th Congress of the European Hematology Association

Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual Meeting

Ads